Comparison of long-term survival between nivolumab plus ipilimumab with chemotherapy and pembrolizumab with chemotherapy in advanced non-small cell lung cancer: A multicenter retrospective cohort study
Open Access
- 19 February 2026
- journal article
- research article
- Published by Elsevier in Lung Cancer
- Vol. 214, 109336
Abstract
No abstract availableKeywords
Funding Information
- Japan Science and Technology Agency
This publication has 33 references indexed in Scilit:
- Comparative Effectiveness of Nivolumab and Ipilimumab Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy in PD-L1 Negative Metastatic Non-Small Cell Lung Cancer PatientsClinical Lung Cancer, 2025
- Efficacy and safety of nivolumab and ipilimumab with or without chemotherapy for unresectable non-small cell lung cancer: a multicenter retrospective observational studyCancer Immunology, Immunotherapy, 2025
- Psoriasis Risk With Immune Checkpoint InhibitorsJAMA Dermatology, 2025
- Real-world outcomes of nivolumab plus ipilimumab and pembrolizumab with platinum-based chemotherapy in advanced non-small cell lung cancer: a multicenter retrospective comparative studyCancer Immunology, Immunotherapy, 2024
- High incidence of cytokine release syndrome in patients with advanced NSCLC treated with nivolumab plus ipilimumabAnnals of Oncology, 2023
- First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in advanced non-small cell lung cancer: a subanalysis of Asian patients in CheckMate 9LAInternational Journal of Clinical Oncology, 2022
- Severe immune-related adverse events of immune checkpoint inhibitors for advanced non-small cell lung cancer: a network meta-analysis of randomized clinical trialsCancer Immunology, Immunotherapy, 2022
- Overlap WeightingJAMA, 2020
- Emerging strategies in cancer therapy combining chemotherapy with immunotherapyCancer Letters, 2019
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)European Journal of Cancer, 2009